Ari Zimran

4.7k total citations
116 papers, 3.5k citations indexed

About

Ari Zimran is a scholar working on Physiology, Molecular Biology and Cell Biology. According to data from OpenAlex, Ari Zimran has authored 116 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Physiology, 46 papers in Molecular Biology and 41 papers in Cell Biology. Recurrent topics in Ari Zimran's work include Lysosomal Storage Disorders Research (94 papers), Cellular transport and secretion (39 papers) and Carbohydrate Chemistry and Synthesis (28 papers). Ari Zimran is often cited by papers focused on Lysosomal Storage Disorders Research (94 papers), Cellular transport and secretion (39 papers) and Carbohydrate Chemistry and Synthesis (28 papers). Ari Zimran collaborates with scholars based in Israel, United States and United Kingdom. Ari Zimran's co-authors include Ernest Beutler, Deborah Elstein, Mia Horowitz, Terri Gelbart, Aya Abrahamov, Carol West, Gregory M. Pastores, Joseph A. Sorge, E A Gross and Pramod K. Mistry and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

Ari Zimran

109 papers receiving 3.3k citations

Peers

Countries citing papers authored by Ari Zimran

Since Specialization

Citations

This map shows the geographic impact of Ari Zimran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ari Zimran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ari Zimran more than expected).

Fields of papers citing papers by Ari Zimran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ari Zimran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ari Zimran. The network helps show where Ari Zimran may publish in the future.

Co-authorship network of co-authors of Ari Zimran

This figure shows the co-authorship network connecting the top 25 collaborators of Ari Zimran. A scholar is included among the top collaborators of Ari Zimran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ari Zimran. Ari Zimran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A large long‐term database of Gaucher disease patients demonstrates increased risk of lymphoma and myeloma, but not of solid tumours 2025 ·Internal Medicine Journal ·(unknown), Tama Dinur, Ora Paltiel, Barbara Silverman, Shoshana Revel‐Vilk, Ari Zimran	0
2	Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey 2025 ·Orphanet Journal of Rare Diseases ·Ari Zimran, Shoshana Revel‐Vilk, Tama Dinur, (unknown), Jaco Botha, (unknown), Pilar Giraldo, Patrick Deegan, Stephan vom Dahl	2
3	Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease 2017 ·Blood ·Ari Zimran, Shoshana Revel‐Vilk, Deborah Elstein, (unknown), Michal Becker‐Cohen, (unknown), Jeff Szer	1
4	Are transient and shear wave elastography useful tools in Gaucher disease? 2016 ·Blood Cells Molecules and Diseases ·Muriel Webb, Ari Zimran, Tama Dinur, Oren Shibolet, (unknown), David M. Steinberg, Ophira Salomon	19
5	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase 2014 ·Gregory M. Pastores, Мilan Petakov, Pilar Giraldo, Hanna Rosenbaum, Jeff Szer, Patrick Deegan, Dominick Amato, Eugen Mengel, Ee Shien Tan, Raul Chertkoff, Einat Brill‐Almon, Ari Zimran	1
6	Velaglucerase alfa: A new option for Gaucher disease treatment 2011 ·Drugs of today ·Ari Zimran	7
7	Mandibular and dental manifestations of Gaucher disease 2011 ·Oral Diseases ·(unknown), Ellen Sidransky, (unknown), Ari Zimran, Deborah Elstein	14
8	Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease 2010 ·Blood Cells Molecules and Diseases ·Deborah Elstein, Gabriel Cohn, (unknown), Maja Djordjevic, (unknown), Ari Zimran	27
9	Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1 2009 ·Genetics in Medicine ·Gregory A. Grabowski, Katherine Kacena, J. Alexander Cole, Carla E. M. Hollak, Lin Zhang, John Yee, Pramod K. Mistry, Ari Zimran, Joel Charrow, Stephan vom Dahl	68
10	Computerized cognitive testing in patients with type I Gaucher disease: Effects of enzyme replacement and substrate reduction 2005 ·Genetics in Medicine ·Deborah Elstein, (unknown), Glen M. Doniger, Ely S. Simon, (unknown), (unknown), Ari Zimran	31
11	TNF-α levels and TNF-α gene polymorphism in type I Gaucher disease 2005 ·Cytokine ·(unknown), Ari Zimran, Helen Michelakakis, Deborah Elstein	24
12	Fibromyalgia and Gaucher's disease 2005 ·QJM ·Ariel Brautbar, Deborah Elstein, (unknown), (unknown), (unknown), Dan Buskila, Ari Zimran	5
13	Rheological determinants in patients with Gaucher disease and internal inflammation 2004 ·American Journal of Hematology ·Ari Zimran, Amir Bashkin, Deborah Elstein, Bernard Rudensky, Rivka Rotstein, Meirav Rozenblat, Tamar Mardi, David Zeltser, Varda Deutsch, Itzhak Shapira, Shlomo Berliner	15
14	High prevalence of complement C7 deficiency among healthy blood donors of Moroccan Jewish ancestry 2001 ·American Journal of Medical Genetics ·David Halle, Deborah Elstein, (unknown), (unknown), Eilat Shinar, Menachem Schlesinger, Ari Zimran	16
15	Epidermal Abnormalities May Distinguish Type 2 from Type 1 and Type 3 of Gaucher Disease 1996 ·Pediatric Research ·Ellen Sidransky, (unknown), Robert Lee, Leon A. Metlay, Steve Abella, Ari Zimran, (unknown), Peter M. Elias, Edward I. Ginns, Walter M. Holleran	72
16	Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. 1993 ·PubMed ·Shoshana Zevin, Aya Abrahamov, Irith Hadas‐Halpern, (unknown), Ephrat Levy‐Lahad, Mia Horowitz, Ari Zimran	39
17	Correction of neutrophil chemotaxis defect in patients with gaucher disease by low‐dose enzyme replacement therapy 1993 ·American Journal of Hematology ·Ari Zimran, Aya Abrahamov, M Aker, Yaacov Matzner	26
18	Low‐dose high‐frequency enzyme replacement therapy for very young children with severe Gaucher disease 1993 ·British Journal of Haematology ·Ari Zimran, Irith Hadas‐Halpern, Shoshana Zevin, Ephrat Levy‐Lahad, Aya Abrahamov	33
19	Analysis of ‘color PCR’ by automatic DNA sequencer 1989 ·Nucleic Acids Research ·Ari Zimran, Charles A. Glass, (unknown), Ernest Beutler	8
20	Reversible cholestatic jaundice and hyperamylasaemia associated with captopril treatment. 1983 ·BMJ ·Ari Zimran, A. S. Abraham, C Hershko	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact